Lumretuzumab
Based on 1 Customer Validation
Lumretuzumab (Anti-Human ERBB3 Recombinant Antibody) is a humanized anti-HER3 (ERBB3) monoclonal antibody. Lumretuzumab effectively inhibits the activity of key oncogenic signaling pathways such as PI3K/AKT and MAPK. Lumretuzumab has been optimized through glycosyl engineering to enhance antibody-dependent cell-mediated cytotoxicity (ADCC). Lumretuzumab can be used to study HER3-positive, HER2-low-expressing solid tumors, especially breast cancer.
For research use only. We do not sell to patients.
- Purity: ≥99.0%
- CAS No.: 1448327-63-6
- Molecular Weight:146.92 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All EGFR Isoforms
More
Biological Activity
Human IgG1 kappa
Human
|
HER3 |
Lumretuzumab (10 μM, 1 h) effectively inhibits HER2, HER3, and AKT phosphorylation after HRG stimulation in MCF-7 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MCF-7 cells
-
Concentration:10 μM
-
Incubation Time:1 h
-
Result:Effectively inhibited the phosphorylation of HER3 and the downstream AKT signaling pathway.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:ER+/HER2-low/HER3+ human breast cancer xenotransplantation model established in female nu/nu mice[2]
-
Dosage:10 mg/kg
-
Administration:Intraperitoneal injection (i.p.), once a week for 40-70 days
-
Result:Specifically inhibited the activation of HER3 and blocks the signal transduction induced by HRG.
Induced tumor arrest, achieved significant tumor regression through combination with Pertuzumab, and the efficacy was optimal when combined with Fulvestrant.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Immobilized HER3 Protein, Human (HEK293, His, HY-P72625) can bind Lumretuzumab. The EC50 for this effect is 3.513 ng/mL. -
Flow cytometric analysis of 1X106 MCF-7 cells with Lumretuzumab (HY-P99304, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS No. 1448327-63-6
-
Appearance Liquid
-
Molecular Weight 146.92 kDa
-
Color Colorless to light yellow
-
SMILES
[Lumretuzumab]
-
Synonyms
Anti-Human ERBB3 Recombinant Antibody
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (261 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Schneeweiss A, et al. Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer. Invest New Drugs. 2018 Oct;36(5):848-859. [Content Brief]
[2]. Collins D, et al. Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer. PLoS One. 2017 May 11;12(5):e0177331. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)